Skip to main content
Smart Investors Daily
MT

NASDAQ · MTP

Midatech Pharma plc

Healthcare · Biotechnology

$0.29

Down-$0.06 (-18.50%)

Updated Aug 23, 2026, 8:46 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.98M
P/E ratio
-0
Dividend yield
0.00%
52-week range
— – —
Volume
164.36K
Avg. volume
1.84M

Price performance

MTP price history

1M range · 0 trading sessions · Daily adjusted prices

MTP does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest MTP news

The latest Smart Investors Daily articles mentioning MTP.

MTP research

Overview

Company profile and research snapshot.

Company profile

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Mar 9, 2022

A Peek Into The Markets: US Stock Futures Surge; Crude Oil Down Over 1%

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 180 points in the previous session. Investors are awaiting earnings results from United Natural Foods, Inc.. (NYSE: UNFI), Campbell Soup Company (NYSE: CPB) and Thor Industries, Inc. (NYSE: THO). The Labor Department's JOLTS report for January will be released at 10:00 a.m. ET. Job openings are likely to hold steady at 10.900 million in January compared to December's higher-than-expected level of 10.925 million. Futures for the Dow Jones Industrial Average surged 473 points to 33,075.00 while the Standard & Poor’s 500 index futures rose 65.75 points to 4,234.50. Futures for the Nasdaq index climbed 246 points to 13,513.00. Oil prices traded lower as Brent crude futures fell 1.2% to trade at $126.43 per barrel, while US WTI crude futures fell 1.5% to trade at $121.82 a barrel. The Energy Information Administration’s weekly report on petroleum inventories in the ...

Benzinga · May 7, 2021

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5 million. The company's, Q1 earnings came out yesterday. Orgenesis (NASDAQ:ORGS) shares moved upwards by 15.38% to $5.25. The market value of their outstanding shares is at $128.1 million. Chemomab Therapeutics (NASDAQ:CMMB) shares moved upwards by 14.4% to $22.71. Nkarta (NASDAQ:NKTX) stock rose 13.81% to $29.5. The company's market cap stands at $969.6 million. ViewRay (NASDAQ:VRAY) shares ...Full story available on Benzinga.com

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.